Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Tuesday

Syndax Pharmaceuticals (NASDAQ:SNDX) is projected to release its Q1 2025 earnings data after the market closes on Tuesday, May 6th. Analysts expect the company to announce earnings of ($1.24) per share and revenue of $15.88 million for the quarter.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The company had revenue of $7.68 million for the quarter, compared to analysts’ expectations of $86.32 million. On average, analysts expect Syndax Pharmaceuticals to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Syndax Pharmaceuticals Price Performance

Shares of SNDX stock opened at $13.73 on Monday. The company has a market cap of $1.18 billion, a PE ratio of -3.78 and a beta of 0.82. Syndax Pharmaceuticals has a 1 year low of $9.66 and a 1 year high of $25.07. The stock’s 50 day simple moving average is $12.89 and its two-hundred day simple moving average is $14.64.

Insider Activity at Syndax Pharmaceuticals

In other news, CFO Keith A. Goldan sold 3,777 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $58,543.50. Following the completion of the transaction, the chief financial officer now directly owns 90,746 shares of the company’s stock, valued at approximately $1,406,563. The trade was a 4.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the completion of the transaction, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,683 shares of company stock worth $336,087 over the last three months. 4.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

SNDX has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. JPMorgan Chase & Co. raised their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, March 20th. StockNews.com upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a report on Thursday, April 10th. Scotiabank decreased their price objective on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. Finally, Citigroup dropped their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $36.20.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).